Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing

R. M. Lloyd, D. A. Burns, J. T. Huong, R. L. Mathis, M. A. Winters, M. Tanner, A. De La Rosa, B. Yen-Lieberman, W. Armstrong, A. Taege, D. R. McClernon, J. L. Wetshtein, Brian M. Friedrich, Monique R. Ferguson, William O'Brien, P. M. Feorino, M. Holodniy

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

A novel method for the collection and transportation of dried-blood-plasma samples, SampleTanker (ST), was developed and compared to standard shipping protocols for frozen-plasma specimens containing human immunodeficiency virus type 1 (HIV-1) and/or hepatitis C virus (HCV). Matched frozen and dried 1-ml EDTA-containing plasma samples were collected and analyzed by several molecular-based virologic assays. After addition of 1.175 ml of reconstitution buffer, 1.035 ml of dried plasma was recovered. Mean intra-assay variances were 0.05, 0.05, and 0.06 log10 copies/ml for the Versant, Amplicor, and NucliSens QT HIV-1 load assays, respectively (P, not significant). However, mean HIV-1 viral load was consistently reduced in dried samples by 0.32 to 0.51 log10 copies/ml, depending on assay type (P < 0.05). Infectious HIV-1 was not recovered from dried ST plasma. There was no significant difference in HIV-1 viral load results obtained using ST after 8 weeks of storage at ambient temperature. Compared to frozen plasma, HIV-1 genotypic results were >99% concordant at the nucleotide and amino acid levels, as well as for resistance-associated mutations. We further demonstrated successful detection of multiple analytes, including HIV-1 viral load, HIV-1 antiretroviral resistance genotype, and HCV genotype, from a single ST unit. Dried plasma collected with ST yielded comparable results to frozen samples for multiple-analyte clinical testing. As such, ST could be a useful alternative for virologic tests and clinical trials worldwide by significantly diminishing transportation cost and the sample volume restrictions associated with dried-blood-spot technology.

Original languageEnglish (US)
Pages (from-to)1491-1496
Number of pages6
JournalJournal of Clinical Microbiology
Volume47
Issue number5
DOIs
StatePublished - May 2009

ASJC Scopus subject areas

  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing'. Together they form a unique fingerprint.

  • Cite this

    Lloyd, R. M., Burns, D. A., Huong, J. T., Mathis, R. L., Winters, M. A., Tanner, M., De La Rosa, A., Yen-Lieberman, B., Armstrong, W., Taege, A., McClernon, D. R., Wetshtein, J. L., Friedrich, B. M., Ferguson, M. R., O'Brien, W., Feorino, P. M., & Holodniy, M. (2009). Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. Journal of Clinical Microbiology, 47(5), 1491-1496. https://doi.org/10.1128/JCM.02354-08